FY2025 Earnings Estimate for ABVX Issued By Leerink Partnrs

ABIVAX Société Anonyme (NASDAQ:ABVX) – Research analysts at Leerink Partnrs decreased their FY2025 earnings estimates for ABIVAX Société Anonyme in a research report issued on Monday, March 24th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($3.36) per share for the year, down from their prior forecast of ($3.00). The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme’s FY2026 earnings at ($3.25) EPS, FY2027 earnings at ($2.91) EPS, FY2028 earnings at ($2.31) EPS and FY2029 earnings at ($0.26) EPS.

A number of other research firms have also weighed in on ABVX. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, ABIVAX Société Anonyme has a consensus rating of “Buy” and an average price target of $38.00.

ABIVAX Société Anonyme Trading Down 5.7 %

ABIVAX Société Anonyme stock opened at $6.43 on Thursday. The business’s 50-day simple moving average is $6.80 and its two-hundred day simple moving average is $8.37. ABIVAX Société Anonyme has a fifty-two week low of $5.50 and a fifty-two week high of $16.63.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of large investors have recently modified their holdings of the business. GAMMA Investing LLC purchased a new stake in ABIVAX Société Anonyme during the 4th quarter valued at about $29,000. R Squared Ltd acquired a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $36,000. Bank of America Corp DE boosted its stake in ABIVAX Société Anonyme by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after buying an additional 1,990 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $85,000. Finally, Guggenheim Capital LLC acquired a new stake in shares of ABIVAX Société Anonyme in the 4th quarter worth $92,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.